IndikationKurzbezeichnungEudraCT-Nr.PhaseTitelStudie aktiv?
ALLGMALL-MOLACT1-BLINA Blast Successor Trial2015-000733-76IIA confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BITE ® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial)ja
ALLGMALL 08/20132013-003466-13IVTherapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapieja
ALLALL-Registern/an/aGMALL ALL-Registerja
AMLShape2019-004536-37IITreatment of MDS / AML patiens with an impending Hematological relapse with Azaci-tidine alone or in combination with PEvonedistat – a randomized phase 2 trialja
AMLETAL3-ASAP2014-003124-44IIIEvaluation of the impact of remission induction chemotherapy prior to allogeneic stemm cell transplantation in relapsed and poor-response patients with AMLja
AMLCPKC412A23012006-006852-37IIIA phase III randomized, double blind study of induction (daunorubicin/cytarabine) and con_solidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diag_nosed patients <60 years of age with FLT3 mutated Acute Myeloid Leukemiaja
AMLBLAST2014-002702-21IIA double-blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 Addition to consolidation therapy in AML patientsja
AMLARO-0132017-001600-29IIIPhase III, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crnolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemiaja
AMLAML-Registern/an/aAML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL)ja
AMLAG120-C-0092016-004907-30IIIA Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapyja
AML2DAUNO (DaunoDouble)2013-003191-12IIIRandomized comparison between two dose levels of daunorobicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia ≤ 60 yearsja
AML / MDSPALOMA2018-002430-21IIPrimary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogeneic cell transplantation in patients with higher risk MDS and oligoblastic AML - the PALOMA studyja
AnämieMOM-M281-0062019-000720-17II/IIIEfficacy and Safety of M281 in Adults with Warm Autoimmune
Hemolytic Anemia: A Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Study with a Long-term Open-label
AnämieEMAA 93452014-000174-19II/IIIEfficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin Aja
AnämieCSEG101A23012017-001746-10IIIA phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus Placebo, wth or without Hydroxyurea/Hydroxycabamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crisis (STAND)ja
AnämieC-935788-0572018-004774-97IIIA Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fastamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemiaja
APLNAPOLEON-Registern/an/aNational Acute Promyelocytic Leukemia (APL) Observational Study Napoleon-Registry of the German AML-Intergroupja
APLAPOLLO2015-001151-68IIIA randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemiaja
2019-001844-221bA multicenter, Phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of BIVV020 in adults with cold agglutinin diseaseja
CLLCLL-RT12018-002492-17IIA Prospective, Open-Label, Multicentre Phase-II-Trial To Evaluate The Efficacy And Safety Of Zanubrutinib (BGB-3111), A BTK Inhibitor, Plus Teslelizumab (BGB-A317), A PD-1 Inhibitor, For Treatment Of Patients With Richter Transformation (CLL-RT1-Trial Of The GCLLSG)ja
CLLCLL-Registern/an/aRegistry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformationja
NHLAlternative C2018-004038-13IIA Prospective Multicenter Phase 2 Study of the Chemotherapy-Free. Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with previously Untreated Follicular Lymphoma (FL) and a High Tumor Burdenja
CLLACP-196 D8220C00008
(Astra Zeneca)
III bA Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemiaja
CMLPONS2016-000618-30IIPhase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatmentja
CMLPonderosaIVBeobachtungsstudie mit Patienten mit CML in allen Phasen, die mit Ponatinib (Iclusig ®) in jeglicher Dosierung behandelt werdenja
CMLNAUT CAMN107ADE22T2015-004998-33n/aMulticenter prospective trial after first unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI a 2nd timeja
CMLFascination2018-002256-33IIFrontline Asciminib combination in chronic phase CMLja
CMLENDURE CML-IX2016-001030-94IIRandomisierte Phase II Studie zur Untersuchung der Sicherheit und Effektivität einer Therapie mit pegyliertem Prolin-Interferon alpha 2b (AOP2014) zur Erhaltung einer tiefen molekularen Remission bei Patienten mit chronischer myeloischer Leukämie – eine randomisierte, multizentrische Phase-II-Studie mit anschließender Nachbeobachtungsphase außerhalb der Studieja
CMLDastop-2 MED3_2017012016-004106-34IIPersistance of major molecular remission in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt: a multicenter prospective trailja
CMLDasaHIT2015-003502-16IIITreatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative ABL-kinase inhibitors (≥2nd line)ja
CMLCAMN107ADE20 NILO-deep-R2015-000968-34IVA Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of treatment with nilotinib 300 mg BIDja
HDHD212014-005130-55IIITreatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADDja
ITPARGX-113-18032019-002100-41IIIA Long-Term, Single-Arm, Open-Label, Multicenter, Phase III Follow-On Trial to Evaluate Safety and Efficacy of Intravenous Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopeniaja
ITPARGX-113-18012019-002100-41IIIA Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopeniaja
MCLPCYC-1143-CA2017-000129-12IIIPhase 3 Study of Ibrutnib in Combination with Venetoklax in Subjects with Mantle Cell Lymphomaja
MCLINCB 50465-205 CITADEL-2052017-003148-19IIA Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3K_ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)ja
MMMP0250-CP201 "MiRRoR"2016-002771-10IIA Phase II open-label, single-arm, multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with refractory and relapsed multiple myelomaja
MM54767414MMY2065LYNX2018-004185-34IIA Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatmentja
MMGMMG-CONCEPT2016-000432-17IIEine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyelomsja
MPNSRA-MMB-3012019-000583-18IIIA Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of
Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic
Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV)
Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who
were Previously Treated with JAK Inhibitor Therapy
MPNSAL-MPN-Registern/an/aSAL-MPN-Register und Biomaterieldatenbank der Studienallianz Leukämie (SAL)ja
MPNMMM 02 study CTC127292014-005210-28IIRuxolitinib versus allogenic stem cell transplantation für patients with myelofibrosis according to donor availability: A prospective phase II (MMM 02study)ja
MPNIMG-7289-CTP-2012019-003659-13IIA Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemiaja
MPNCINC424BDE12 PaVe-NISn/an/aPaVe - Eine prospektive, nicht-interventionelle Studie zur JAKAVI®-Behandlung von Patienten mit Polycythaemia veraja
MPNBesremi-PASS EUPAS29462n/aII bA Prospective, Multicentre, Non-interventional,
Observational, Post-authorisation Safety Study of
Ropeginterferon alfa-2b in Polycythaemia Vera Patients
MZoLOLYMP-12017-003149-56IIPhase II, single arm, multicentric, open label, non-randomized: Obinutuzumab in marginal zone lymphomaja
MZoLMarginalzonenlymphom-Registern/an/aNicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomenja
MZoLINCB 50465-204 CITADEL-2042017-000970-12IIA Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3K_ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphome With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)ja
NHL agg.TIGER-Studie
2019-002930-35IIPhase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Ag-gressive B-cell Non-Hodgkin Lymphomaja
NHL agg.SGN35-014 "ECHELON-2"2012-002751-42IIIA randomized, double-blind, placebo-controlled, phase 3 study of CH-P and brentuximab vedotin versus CHOP in the front-line treatment of patients with CD30_positive mature T-cell lymphomasja
NHL agg.Ro-CHOP2012-001580-68IIIPhase 3 multi-center randomized study to compare efficacy and safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphomaja
NHL agg.ImbruVeRCHOP2015-003429-32n/aIbrutinib, Bortezomib s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2ja
NHL agg.MB-CART2019.1
2018-001253-27I/IIA Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHLja
NHL agg.DSHNHL 2015-1 NIVEAU2016-002272-27n/aImprovement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Diseaseja
NHL ind.ML29941 GAZAI2016-002059-89I/ IITherapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaroja
NHL ind.HOVON 110 FL ReBeL Study2011-000097-56I/IIA randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma.ja
NHL ind.GABe 20162016-000755-27IIIFirst line therapy of advanced stage follicular lymphoma in patients not eligible for standard immunochemotherapy. Prospective randomized comparison of single agent GA101 versus GA101 plus bendamustine followed by GA101 in medically non-fit patientsja
PNHCLNP023X22012017-000888-33IIIAn open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in Patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysisja
PNHBP39144 "Composer"2016-002128-10I/IIAn adaptive phase I/II study to assess safety, efficacy, phamacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)ja
Commodore 2 naive
2019-004931-21IIIA phase 3, randomized, open label, active controlles, multicenter study, evaluating the efficacy and safety of Crovalimab versus Eculizumab in Adult and andolescent patients with paroxismal nocturnal Hemoglobinuria not previously treated with complement inhibitors.ja
PNHAPL2-3072019-001106-23IIIAn Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).ja
ZNSMARTA2016-001628-72IIMultizentrische Phase II-Studie zur altersadaptierten Hochdosistherapie gefolgt von autologer Stammzelltransplantation bei fitten älteren Patienten > 65 Jahren mit primär zerebralem Lymphomja
CLLCLL 172019-003854-99IIIA phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL)ja
Commodore 1 switch
2019-004931-21IIIA Phase III, randomized, open-label, active-controlled, multicenter study evaluating the
efficacy and safety of crovalimab versus eculizumab in adult and adolescent patients
with PNH currently treated with complement inhibitors
MPNM16-191IIIA Randomized, Open-Label, Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib Alone in Subjects with Myelofibrosis, Transform-1ja
PNHCLNP023C123022019-004665-40IIIA randomized, multicenter, active-comparator controlled, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatment with an intravenous anti-C5 antibodyja
NHL agg.Coachn/an/aComprehensive Analysis of Immune Checkpoint Inhibition in Relapsed Hodgkin Lymphomaja
AL-AmyloidoseCAEL301-3012019_004254_28IIIA Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosisja
AL-AmyloidoseCAEL301-3022020-000713-32IIIA Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosisja
WaihaANX-wAIHA-01n/an/a“A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia “ja
AMLTUD-MOSAIC-0752019-003863-23IIMultizentrische Studie mit Phase-I-Teil im 3+3 Studiendesign (MODULE) und
einem randomisiert kontrollierten doppelblinden (MAGNOLIA) und
randomisierten unverblindeten (MAGMA) Phase-II-Teil
CADLTS166372019-004423-211bAn open label, long term, safety and tolerability study of patients with cold agglutinin disease previously treated with BIVV020ja
AMLRelax2018-003025-28I / IIPhase-I/II trial for relapsed or refractory AML patients
combining cytarabine and mitoxantrone with venetoclax